FDA's Pazdur, Quoted in The Hill, On Changes in Cancer Research

FDA's Pazdur, Quoted in The Hill, On Changes in Cancer Research

06.05.12 | By Kate Connors

In The Hill today, reporter Elise Viebeck reports from the recent American Society of Clinical Oncology meeting about the increasing number of new cancer medicines reaching the Food and Drug Administration for review - and the groundbreaking nature of many of these new medicines.

I urge you to read the article. It's not long, but it's incredibly enlightening. And for an abbreviated version, I'd definitely highlight this quote from Richard Pazdur, head of FDA's Office of Hematology and Oncology drugs. He said that the new profiles of so-called breakthrough drugs - such as those that more directly target the cancer cell rather than the tissue around it - call for increased collaboration and communication between the agency and the biopharmaceutical companies sponsoring the new medicine:

"When we are seeing drugs with a high degree of efficacy ... it requires a different interaction with the companies," he said. "We may change the registration strategy or the size of the trial."

More On PhRMA — powered by PhRMApedia